Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA).

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Clin Infect Dis. 1999 May;28(5):1025-31. Unique Identifier : AIDSLINE MED/99379698
Vazquez JA; Sobel JD; Peng G; Steele-Moore L; Schuman P; Holloway W; Neaton JD; Division of Infectious Diseases, Wayne State University School of; Medicine, Detroit, Michigan, USA. jvazquez@oncgate.roc.wayne.edu

Abstract: The effect of fluconazole prophylaxis on the vaginal flora of 323 human immunodeficiency virus-infected women was evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. Women with CD4 cell counts of < or = 300/mm3 received either 200 mg of fluconazole per week or placebo. Vaginal surveillance cultures were performed every 3 months. After a follow-up of 29 months, Candida albicans was recovered from 53% of patients receiving fluconazole and 68% of patients assigned placebo. Fluconazole was associated with a 50% reduction in the odds of being colonized with C. albicans but with higher rates for non-albicans Candida species. Candida glabrata was recovered from 40 women assigned fluconazole and 29 assigned placebo (relative odds, 1.96; 95% confidence interval, 0.98-3.94). Fluconazole had an early and persistent effect on the vaginal mycoflora, with the emergence of C. glabrata vaginal colonization within the first 6 months. The effect of fluconazole prophylaxis can be attributed to the reduction in vaginal C. albicans colonization; however, C. glabrata colonization rapidly supervened.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL *Antibiotic Prophylaxis Antibiotics, Antifungal/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*MICROBIOLOGY/PREVENTION & CONTROL Candida/CLASSIFICATION/*ISOLATION & PURIF Candida albicans/DRUG EFFECTS/ISOLATION & PURIF Candidiasis, Vulvovaginal/*MICROBIOLOGY/PREVENTION & CONTROL CD4 Lymphocyte Count Double-Blind Method Female Fluconazole/*THERAPEUTIC USE Human Risk Factors
991230
A99C1046

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .